Ruti Aga: Six-Year Ban, a Forged Prescription and the Silence After a Race With No Time

There was a half marathon in China in March. Ruti Aga won it. The official record does not carry the time, the splits, the strength of the field or the prize money. What it carries is a six-year ban effective from 10 September. That is the date in the Athletics Integrity Unit (AIU) statement issued on Thursday, and it is the only clock this case actually runs on. I keep two notebooks—one for the score, one for the silence after it. In this case the first notebook is blank. The second has six years written in it.

According to the AIU, the 32-year-old Ethiopian marathoner returned a positive sample after winning a half marathon in China in March. The substance was methylprednisolone. Aga said it was taken to treat a knee injury. What the investigation produced was less a story about medicine than a story about paperwork: the prescription was written by a family member with no medical registration; the clinic named on the prescription did not exist; and the person claimed to have used an old prescription pad from a former workplace. The clinic explicitly disowned any link to that pad.

The arithmetic is straightforward. Two years for the presence violation. Four years for tampering. Six years in total, from 10 September. That date is also the start of the provisional suspension, so it is a procedural adjustment, not a discount. Aga's 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors remain on her record because the case is anchored to a later race. But the result and prize money from the March half marathon are very likely to be annulled under standard AIU practice; the statement does not spell out the disqualification scope.

One technical correction has to be made first, because several reports framed this as a steroid bust. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List. Anabolic steroids sit in S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. The case therefore turned on route and timing, not on 'steroid use'. A therapeutic knee injection is entirely legal out-of-competition; it becomes a violation only if residues are present in-competition. A road race's testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught.

That gave Aga a legitimate defence pathway. She could have argued medical necessity, route and timing. Instead, the prescription she produced failed at three independent levels: no clinic, no registered doctor, no genuine pad. The forged document destroyed the one defence that might have worked. That is the hardest lesson here: the paperwork became a bigger offence than the medicine.

I went looking for a match and found a room where nobody was keeping score. In the years I have spent watching road racing, the same picture keeps returning: around an elite marathoner sits an informal ring of coaches, agents, physios and 'doctors', and nobody is accountable for every piece of paper. The knee injury is the real beginning of this case. Chronic knee trouble is not an acute misfortune in distance running; it is a career-long condition. The pressure to mask pain and make the start line rises because appearance fees and contracts depend on running. Glucocorticoids are the cheapest, most available tool for that pressure.

But the cheap tool came with a cheap process, and that is where the case broke. An athlete with a credentialed team physician would either hold or apply for a Therapeutic Use Exemption, or observe the WADA route-specific washout period. Neither appears to have happened. When questions were asked, the answer was a prescription written by someone who was not on any medical register. This is not simply an athlete's mistake. It is a picture of a system in which treatment begins before documentation and documentation is produced only after an investigation starts.

The sanction arithmetic carries another signal. Two years for presence and four for tampering is consistent with the Code's standard structure. The two-year presence term also implies that the panel rejected the 'no significant fault' mitigation that could have reduced it further. The four-year tampering term rests on the document and on statements made in interview. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention, but here three independent verification checks failed: the clinic did not exist, the doctor was not registered, the pad was not genuine. That is difficult to call a translation error.

In career terms, the ban is close to terminal. At 32, a six-year suspension pushes any return to around 38. Ethiopian women's marathon depth is so extreme that even a 2:18–2:20 performer is not automatically selectable. A 38-year-old returning with a doping record has effectively no selection pathway. The 2028 Olympic cycle will be defined for her not by a calendar but by absence.

Reading this case only as a steroid bust misreads it. It is primarily a document case, not a drug case. There is no solid evidence that glucocorticoids enhance endurance performance, yet the ban runs six years—because the offence was not the substance but the paper trail built around it. That makes comparisons with anabolic-steroid cases misleading. At the same time, forgery cannot be waved away; in an anti-doping system, a false document is not just a defence, it is an attempt to divert an investigation.

The harder question is what would have happened if Aga had a credentialed team doctor, a recorded treatment and a clean TUE process. That question is not an excuse. It is a way of seeing whom the road-racing economy protects and whom it leaves exposed. China's label-race circuit has been a lucrative, low-risk income tier for East African marathoners. It is now one of the AIU's highest-yield testing grounds. The appearance-fee economy and the testing economy are colliding in the same races.

The next story is already in the pipeline. Where the same informal medical networks serve many athletes in the same training clusters, one case surfacing can mean other files are sitting quietly. The AIU's frontier is shifting from sample detection to document verification. Prescription, clinic, registration, interview—all of it now needs the same scrutiny as the sample. Where the agent and the manager were is not in the statement, but the question remains outside it.

A film that collapses still leaves its rushes; I write from the fragments. The fragments here are these: a won half marathon with no time, a 2026 Tokyo title nobody has yet taken away, a knee that was treated but not recorded, and a prescription no doctor wrote. The six-year ban puts those fragments in an order. The question for the next marathoner who stands on a start line with a sore knee is whether she will have medical support or only an old prescription pad. The answer will not come from the sanction. It will come from a system we are still not watching.